Disc Medicine FY2024 EPS Estimate Raised by Leerink Partnrs

Disc Medicine, Inc. (NASDAQ:IRON - Free Report) - Leerink Partnrs boosted their FY2024 earnings estimates for shares of Disc Medicine in a research note issued to investors on Tuesday, November 12th. Leerink Partnrs analyst T. Smith now forecasts that the company will post earnings of ($3.97) per share for the year, up from their prior forecast of ($4.08). The consensus estimate for Disc Medicine's current full-year earnings is ($4.15) per share. Leerink Partnrs also issued estimates for Disc Medicine's Q4 2024 earnings at ($0.99) EPS, FY2025 earnings at ($5.75) EPS, FY2026 earnings at ($8.21) EPS, FY2027 earnings at ($9.37) EPS and FY2028 earnings at ($8.22) EPS.

Several other equities analysts also recently commented on IRON. Raymond James upgraded shares of Disc Medicine from an "outperform" rating to a "strong-buy" rating and upped their price target for the company from $66.00 to $110.00 in a report on Monday, November 4th. HC Wainwright upped their price target on shares of Disc Medicine from $70.00 to $118.00 and gave the company a "buy" rating in a report on Wednesday. Morgan Stanley raised shares of Disc Medicine from an "equal weight" rating to an "overweight" rating and set a $85.00 price objective for the company in a research report on Tuesday, November 5th. Cantor Fitzgerald reissued an "overweight" rating and issued a $85.00 price objective on shares of Disc Medicine in a research report on Tuesday, October 15th. Finally, Wells Fargo & Company began coverage on shares of Disc Medicine in a research report on Thursday, August 22nd. They issued an "overweight" rating and a $75.00 price objective for the company. Nine equities research analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the stock. According to MarketBeat.com, Disc Medicine has an average rating of "Buy" and a consensus price target of $85.80.

Disc Medicine Stock Down 2.0 %

NASDAQ:IRON traded down $1.21 during mid-day trading on Friday, hitting $59.46. 270,748 shares of the stock traded hands, compared to its average volume of 355,189. The stock has a market capitalization of $1.77 billion, a price-to-earnings ratio of -14.94 and a beta of 0.60. Disc Medicine has a 52 week low of $25.60 and a 52 week high of $77.60. The firm's 50 day moving average is $51.20 and its two-hundred day moving average is $44.97.

Disc Medicine (NASDAQ:IRON - Get Free Report) last issued its quarterly earnings results on Tuesday, November 12th. The company reported ($0.89) EPS for the quarter, beating the consensus estimate of ($1.04) by $0.15.

Institutional Investors Weigh In On Disc Medicine

Several hedge funds have recently modified their holdings of IRON. Atlas Venture Life Science Advisors LLC lifted its position in Disc Medicine by 9.7% during the second quarter. Atlas Venture Life Science Advisors LLC now owns 2,509,456 shares of the company's stock valued at $113,101,000 after acquiring an additional 222,223 shares during the last quarter. Wellington Management Group LLP lifted its position in Disc Medicine by 4.8% during the third quarter. Wellington Management Group LLP now owns 1,840,226 shares of the company's stock valued at $90,429,000 after acquiring an additional 83,731 shares during the last quarter. Frazier Life Sciences Management L.P. lifted its position in Disc Medicine by 123.5% during the second quarter. Frazier Life Sciences Management L.P. now owns 1,754,834 shares of the company's stock valued at $79,090,000 after acquiring an additional 969,834 shares during the last quarter. Deerfield Management Company L.P. Series C lifted its position in Disc Medicine by 53.8% during the second quarter. Deerfield Management Company L.P. Series C now owns 1,023,265 shares of the company's stock valued at $46,119,000 after acquiring an additional 357,730 shares during the last quarter. Finally, Price T Rowe Associates Inc. MD lifted its position in Disc Medicine by 59.8% during the first quarter. Price T Rowe Associates Inc. MD now owns 944,213 shares of the company's stock valued at $58,788,000 after acquiring an additional 353,382 shares during the last quarter. Hedge funds and other institutional investors own 83.70% of the company's stock.

Insider Transactions at Disc Medicine

In other news, Director William Richard White sold 7,136 shares of the company's stock in a transaction that occurred on Monday, November 4th. The shares were sold at an average price of $58.61, for a total value of $418,240.96. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. In the last quarter, insiders sold 7,538 shares of company stock valued at $437,875. Company insiders own 4.24% of the company's stock.

Disc Medicine Company Profile

Disc Medicine, Inc, together with its subsidiaries, a clinical-stage biopharmaceutical company, engages in the discovery, development, and commercialization of novel treatments for patients suffering from serious hematologic diseases in the United States. The company has assembled a portfolio of clinical and preclinical product candidates that aim to modify fundamental biological pathways associated with the formation and function of red blood cells, primarily heme biosynthesis and iron homeostasis.